Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (32)
Manoj Kumar, Selvasankar Murugesan, Nazira Ibrahim, Mamoun Elawad & Souhaila Al Khodor. (2024) Predictive biomarkers for anti-TNF alpha therapy in IBD patients. Journal of Translational Medicine 22:1.
Crossref
Crossref
Dan Vălean, Roxana Zaharie, Roman Țaulean, Lia Usatiuc & Florin Zaharie. (2024) Recent Trends in Non-Invasive Methods of Diagnosis and Evaluation of Inflammatory Bowel Disease: A Short Review. International Journal of Molecular Sciences 25:4, pages 2077.
Crossref
Crossref
Emma Buchan, Jonathan James Stanley Rickard & Pola Goldberg Oppenheimer. (2023) Raman spectroscopic molecular fingerprinting of biomarkers for inflammatory bowel disease. Clinical and Translational Medicine 13:11.
Crossref
Crossref
Fang Wang, Xiaofei Li, Yanting Shi, He Zhou, Gang Yang, Ruixia Li, Tong Wu & Jie Liang. (2023) Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study. Frontiers in Pharmacology 14.
Crossref
Crossref
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan & Yan Zhang. (2023) Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World Journal of Gastroenterology 29:29, pages 4481-4498.
Crossref
Crossref
M. V. Kruchinina, I. O. Svetlova, M. F. Osipenko, N. V. Abaltusova, A. A. Gromov, A. V. Borisova & E. V. Kruchinina. (2023) The significance of serum marker levels for assessing the status and prognosis of patients with inflammatory bowel disease. Experimental and Clinical Gastroenterology:4, pages 121-132.
Crossref
Crossref
Ofra Kriger-Sharabi & Uri Kopylov. (2023) Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn’s Disease. Journal of Clinical Medicine 12:7, pages 2696.
Crossref
Crossref
Yiyoung Kwon, Eun-Sil Kim, Yoon-Zi Kim, Yon-Ho Choe & Mi-Jin Kim. (2022) Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease. Biomedicines 10:10, pages 2372.
Crossref
Crossref
Duaa Ahmed Elhag, Manoj Kumar, Marwa Saadaoui, Anthony K. Akobeng, Fatma Al-Mudahka, Mamoun Elawad & Souhaila Al Khodor. (2022) Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. International Journal of Molecular Sciences 23:13, pages 6966.
Crossref
Crossref
Laura A. Lucaciu, Maria Ilieș, Ștefan C. Vesa, Radu Seicean, Shahida Din, Cristina Adela Iuga & Andrada Seicean. (2021) Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease. Journal of Personalized Medicine 11:11, pages 1130.
Crossref
Crossref
Allan E. Stolarski, Jiyoun Kim, Qiuyang Zhang & Daniel G. Remick. (2021) Cytokine Drizzle—The Rationale for Abandoning “Cytokine Storm”. Shock 56:5, pages 667-672.
Crossref
Crossref
Sheng-long Xia, Quan-jia Min, Xiao-xiao Shao, Dao-po Lin, Guo-long Ma, Hao Wu, Shu-guang Cao & Yi Jiang. (2021) Influence of Vitamin D3 Supplementation on Infliximab Effectiveness in Chinese Patients With Crohn's Disease: A Retrospective Cohort Study. Frontiers in Nutrition 8.
Crossref
Crossref
Tim Raine, Bram Verstockt, Uri Kopylov, Konstantinos Karmiris, Rimma Goldberg, Raja Atreya, Johan Burisch, John Burke, Pierre Ellul, Charlotte Hedin, Stefan D Holubar, Konstantinos Katsanos, Triana Lobaton, Carsten Schmidt & Garret Cullen. (2021) ECCO Topical Review: Refractory Inflammatory Bowel Disease. Journal of Crohn's and Colitis 15:10, pages 1605-1620.
Crossref
Crossref
Dario Sorrentino & James M Gray. (2021) Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 27:8, pages 1237-1247.
Crossref
Crossref
Jana G. Hashash & Fadi H. Mourad. (2021) Positioning biologics in the management of moderate to severe Crohn's disease. Current Opinion in Gastroenterology 37:4, pages 351-356.
Crossref
Crossref
Yueying Chen, Hanyang Li, Qi Feng & Jun Shen. (2021) Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients. Frontiers in Pharmacology 12.
Crossref
Crossref
Dario Sorrentino, Vu Q. Nguyen & Kim Love. (2021) Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease. Digestive Diseases 39:6, pages 626-633.
Crossref
Crossref
Beatriz Mateos, Esteban Sáez-González, Inés Moret, David Hervás, Marisa Iborra, Elena Cerrillo, Luis Tortosa, Pilar Nos & Belén Beltrán. (2021) Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn’s Disease Response to Infliximab, as Assessed by Calprotectin Log Drop. Digestive Diseases 39:1, pages 1-9.
Crossref
Crossref
Raja Atreya, Markus F. Neurath & Britta Siegmund. (2020) Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. Frontiers in Medicine 7.
Crossref
Crossref
Lorenzo Bertani, Matteo Fornai, Luca Antonioli & Corrado Blandizzi. (2020) Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab—authors' reply. Alimentary Pharmacology & Therapeutics 52:6, pages 1082-1082.
Crossref
Crossref
Lorenzo Bertani, Matteo Fornai, Marco Fornili, Luca Antonioli, Laura Benvenuti, Gherardo Tapete, Giovanni Baiano Svizzero, Linda Ceccarelli, Maria Gloria Mumolo, Laura Baglietto, Nicola de Bortoli, Massimo Bellini, Santino Marchi, Francesco Costa & Corrado Blandizzi. (2020) Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Alimentary Pharmacology & Therapeutics 52:2, pages 284-291.
Crossref
Crossref
Javier P Gisbert & María Chaparro. (2020) Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 14:5, pages 694-709.
Crossref
Crossref
Lorenzo Bertani, Gian Paolo Caviglia, Luca Antonioli, Rinaldo Pellicano, Sharmila Fagoonee, Marco Astegiano, Giorgio Maria Saracco, Elisabetta Bugianesi, Corrado Blandizzi, Francesco Costa & Davide Giuseppe Ribaldone. (2020) Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. Journal of Clinical Medicine 9:5, pages 1323.
Crossref
Crossref
Peng Chen, Gaoshi Zhou, Jingxia Lin, Li Li, Zhirong Zeng, Minhu Chen & Shenghong Zhang. (2020) Serum Biomarkers for Inflammatory Bowel Disease. Frontiers in Medicine 7.
Crossref
Crossref
Lorenzo Bertani, Luca Antonioli, Matteo Fornai, Gherardo Tapete, Giovanni Baiano Svizzero, Santino Marchi, Corrado Blandizzi & Francesco Costa. (2020) Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterologica e Dietologica 65:4.
Crossref
Crossref
Ariela K. Holmer, Robert Battat, Parambir S. Dulai, Niels Vande Casteele, Nghia Nguyen, Anjali Jain, Ara Miralles, Jennifer Neill, Helen Le, Siddharth Singh, Jesus Rivera-Nieves, William J. Sandborn & Brigid S. Boland. (2020) Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease. Therapeutic Advances in Gastroenterology 13, pages 175628482097121.
Crossref
Crossref
Nurulamin M Noor, Bram Verstockt, Miles Parkes & James C Lee. (2020) Personalised medicine in Crohn's disease. The Lancet Gastroenterology & Hepatology 5:1, pages 80-92.
Crossref
Crossref
Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi & Reza Malekzadeh. (2019) Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report. Middle East Journal of Digestive Diseases 12:1, pages 12-18.
Crossref
Crossref
Koji Kimura, Atsushi Yoshida, Fumihiko Katagiri, Risa Takayanagi & Yasuhiko Yamada. (2019) Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharmaceutics & Drug Disposition 40:7, pages 250-261.
Crossref
Crossref
Luca Viganò, Michela Mineccia, Franco Bertolino, Francesco Giraldi, Caterina Rigazio, Rodolfo Rocca & Alessandro Ferrero. (2019) Intraoperative ultrasonography in patients undergoing surgery for Crohn’s disease. Prospective evaluation of an innovative approach to optimize staging and treatment planning. Updates in Surgery 71:2, pages 305-312.
Crossref
Crossref
Boris Gole & Uroš Potočnik. (2019) Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis. Cells 8:6, pages 515.
Crossref
Crossref
Toer W. Stevens, Mijntje Matheeuwsen, Maria H. Lönnkvist, Claire E. Parker, Manon E. Wildenberg, Krisztina B. Gecse & Geert R. D’Haens. (2018) Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancy. Alimentary Pharmacology & Therapeutics 48:11-12, pages 1213-1231.
Crossref
Crossref